The Application Of Neoadjuvant Therapy In Thoracic Esophageal Squamous Cell Carcinoma

According to the article "Cancer statistics in China 2015", esophageal cancer is the fourth most common cause of cancer-related deaths in China, and more than 90% of these are from esophageal squamous carcinoma, and more than half of these patients were diagnosed at an advanced stage. For locally advanced esophageal cancer in Western countries, neoadjuvant chemotherapy or chemoradiotherapy are the standard treatments of choice, especially for esophageal squamous carcinoma. Neoadjuvant chemotherapy, rather than chemoradiotherapy, has been incorporated into the standard treatment strategy for resectable esophageal squamous cell carcinoma in Japan, according to the results of the JCOG9907 trial. In many Asian countries such as China, few large, prospective, randomized studies have investigated the value and optimal application of neoadjuvant therapy followed by surgery for patients with locally advanced resectable esophageal squamous cell carcinoma. At present, the application of neoadjuvant therapy in thoracic esophageal squamous cell carcinoma in many Asian countries has conflicting results in published studies.